AXLRx Book a callCommission

01 · Market Intelligence · Analysis type · 23 published

KOL Mapping

A six-sheet KOL universe and engagement workbook, built gate by gate: sizing, tier classification, scientific influence, engagement readiness, MSL territory coverage, and cross-border network. Every KOL entry carries a verification tag.

Every KOL Mapping analysis

KOL · Rare Disease · Medical Affairs · Medical Affairs GCC Hereditary Angioedema KOL Mapping KFSH&RC, AUH, and Hamad Medical Corporation anchor a GCC HAE specialist community that SACIA sizes at just 6-10 physicians regionwide. That concentration is exactly what this workbook sizes before any individual name enters it. GCC · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Rare Disease · Medical Affairs · Medical Affairs UK ATTR Amyloidosis KOL Mapping The National Amyloidosis Centre holds the clinical-expert seat at every NICE ATTR appraisal to date. This workbook sizes the UK ATTR KOL network before a name enters it: NAC's 400-500-patient ATTRv surveillance registry, the separate UCL and Queen Elizabeth Hospital Birmingham National ATTRv Registry tracking approximately 800 patients, and the roughly 30 NHS centres running Tc-PYP scintigraphy nationally. UK · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Rare Disease · Medical Affairs · Medical Affairs GCC Dravet Syndrome KOL Mapping A five-institution Saudi consortium across Riyadh, Jeddah and Dammam tracked 44 Dravet patients on stiripentol combination therapy. That kind of coordinated, cross-city publication is exactly the institutional signal this workbook sizes before any individual name enters it. GCC · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Rare Disease · Medical Affairs · Medical Affairs UK Sickle Cell Disease KOL Mapping Four London teaching hospitals anchor roughly 6,000 of the UK's 15,000-17,000 sickle cell patients. Barts, King's, Imperial and Homerton, with Birmingham Heartlands, Manchester, Bristol and Nottingham forming the next ring. That eight-centre structure is exactly the institutional signal this workbook sizes before any individual name enters it. UK · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Rare Disease · Medical Affairs · Medical Affairs UK Spinal Muscular Atrophy KOL Mapping Four NHS Highly Specialised Services networks and six designated gene-therapy centres carry the UK SMA treatment pathway. This workbook sizes that institutional structure, plus the Bristol Institute of Child Health attenuation-cohort follow-up, before any physician name enters it. UK · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Rare Disease · Medical Affairs · Medical Affairs GCC Fabry Disease KOL Mapping KFSH&RC runs the only HEK293 amenable-mutation assay in the GCC. Its formulary committee recommendation drives NPHC coverage decisions for every Fabry disease treatment. That kind of single-institution gatekeeping is exactly the concentration this workbook sizes before any individual name enters it. GCC · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Rare Disease · Medical Affairs · Medical Affairs GCC Myasthenia Gravis KOL Mapping Just 10-15 neuromuscular neurologists across six named GCC referral centres manage 70-80% of confirmed generalised myasthenia gravis. That concentration is exactly what this workbook sizes before any individual name enters it. GCC · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Rare Disease · Medical Affairs · Medical Affairs GCC Pompe Disease KOL Mapping Six to eight named metabolic centres across the GCC hold ERT infusion capacity for Pompe disease. KFSH&RC leads with roughly 120 patients over 15 years. That kind of institutional concentration is exactly what this workbook sizes before any individual name enters it. GCC · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Rare Disease · Medical Affairs · Medical Affairs UK PNH KOL Mapping Fewer than 25 consultants manage over 90% of the UK's PNH caseload. They sit across five NHS Highly Specialised Services centres anchored by the Leeds National PNH Service. That kind of institutional concentration is exactly the signal this workbook sizes before any individual name enters it. UK · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Oncology · Medical Affairs · Medical Affairs UK Breast Cancer HR+/HER2- KOL Mapping A single five-centre South West England consortium tracks 666 UK patients across all three approved CDK4/6 inhibitors. That kind of coordinated, multi-centre evidence generation is exactly the institutional signal this workbook sizes before any individual name enters it. UK · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Rare Disease · Medical Affairs · Medical Affairs UK Dravet Syndrome KOL Mapping Six NHS centres concentrate the UK's refractory Dravet syndrome cohort. Great Ormond Street, Bristol, Alder Hey, Birmingham Children's, Leeds and Newcastle. The British Paediatric Neurology Association's Dravet working group shapes NICE evidence review 18-24 months ahead of submission, and that institutional network is what this workbook sizes first, not a roster of named physicians. UK · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Rare Disease · Medical Affairs · Medical Affairs UK Pompe Disease KOL Mapping A six-physician BIMDG subcommittee advises NICE directly on Pompe disease. It sits at the centre of a five-centre UK Pompe Consortium and an eight-centre NHS Highly Specialised Service network. That kind of institutional concentration is exactly what this workbook sizes before any individual name enters it. UK · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Rare Disease · Medical Affairs · Medical Affairs GCC Spinal Muscular Atrophy KOL Mapping Four designated GCC centres carry nearly all regional SMA gene-therapy and specialist referral activity. KAMC and KFSH&RC in Riyadh, Sidra Medicine in Doha, and SKMC in Abu Dhabi. This workbook sizes that institutional concentration before any individual name enters it. GCC · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Rare Disease · Medical Affairs · Medical Affairs UK IgA Nephropathy KOL Mapping The Renal Association's IgAN guideline committee, not any single physician, sets the reference point NICE checks against. This workbook sizes that committee and the network behind it before individual outreach begins. UK · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Rare Disease · Medical Affairs · Medical Affairs GCC Sickle Cell Disease KOL Mapping Only three GCC institutions run structured adult sickle cell programmes for 200,000-250,000 patients. KFSH&RC, KAMC and AUH. That three-centre concentration, anchored by the KFSH&RC Dammam flagship and 12+ MOH regional centres in Eastern Province, is exactly the institutional signal this workbook sizes before any individual name enters it. GCC · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Rare Disease · Medical Affairs · Medical Affairs FR PNH KOL Mapping Saint-Louis Hospital anchors France's MaRIH-coordinated PNH reference network of 14 competence centres. Only 24 of the 50-plus centres in the national clone-observatory network actively report into it. That kind of institutional structure is exactly what this workbook sizes before any individual name enters it. FR · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Oncology · Medical Affairs · Medical Affairs US Breast Cancer HR+/HER2- KOL Mapping A 9,146-patient US real-world study found no significant survival difference between palbociclib, ribociclib, and abemaciclib. When the drugs perform equivalently, KOL guidance decides which one gets prescribed, not clinical data. US · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Rare Disease · Medical Affairs · Medical Affairs UK Hereditary Angioedema KOL Mapping Five NHS specialist centres manage more than 90% of UK HAE patients. Sheffield, Cambridge, Birmingham, Guy's and St Thomas', and Manchester. That concentration is what this workbook sizes before any physician enters the K1-K6 gate structure. UK · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Rare Disease · Medical Affairs · Medical Affairs UK Fabry Disease KOL Mapping Royal Free London's National Fabry Service was NICE's appointed clinical expert twice over. It advised on both migalastat's HST4 and pegunigalsidase alfa's TA915, across a network of five named NHS lysosomal storage disorder centres. That repeated appointment is exactly the institutional signal this workbook sizes before any individual name enters it. UK · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Rare Disease · Medical Affairs · Medical Affairs UK Myasthenia Gravis KOL Mapping A 30-centre NHS neuromuscular network coordinated through Muscular Dystrophy UK carries UK myasthenia care. That network, plus a 3,000-member Myasthenia Gravis Association UK patient registry, is the institutional signal this workbook sizes before any individual name enters it. UK · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Rare Disease · Medical Affairs · Medical Affairs GCC ATTR Amyloidosis KOL Mapping KFSH&RC maintains the only GCC-wide ATTRv genetic registry and houses the region's nuclear cardiology programme. Fewer than 8 named cardiology and scintigraphy centres region-wide, spanning KAMC, AUH, HMC Doha, and OCCI Muscat, define a small institutional field this workbook sizes before any individual name enters it. GCC · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Rare Disease · Medical Affairs · Medical Affairs GCC IgA Nephropathy KOL Mapping GCC IgA nephropathy expertise concentrates in five named tertiary centres. Roughly 300 practising nephrologists work the region, of whom 30 to 50 carry glomerular-disease subspecialty interest. This workbook sizes that concentrated institutional base before any individual name enters it. GCC · In-Market · 24–32 pp · PDF · Excel · PPT KOL · Rare Disease · Medical Affairs · Medical Affairs GCC PNH KOL Mapping Seven institutions across Riyadh, Jeddah, Dubai and Abu Dhabi hold the GCC's confirmed PNH caseload. Just 5 to 8 physicians function as genuine adoption gatekeepers. That kind of concentration is exactly what this workbook sizes before any individual name enters it. GCC · In-Market · 24–32 pp · PDF · Excel · PPT

KOL Mapping — frequently asked

What formats are included?

An editable 6-sheet Excel KOL workbook (Universe, Tier Scoring, Engagement Calendar, MSL Territory, Cross-Border Network, Evidence Register), a PDF summary brief, and a 45-minute analyst call.

How are KOL identities and rankings verified?

Every KOL entry is built from live PubMed, ClinicalTrials.gov, and guideline-authorship data, then tagged Verified / Industry benchmark / Requires client validation — no name ships unverified.

Can I scope this to a specific country or institution set?

Yes. You set the indication, geography, and institution scope; the workbook is built to your scope and delivered editable.